Stanford et al., 2015 - Google Patents
Prospective evaluation of blood coagulability and effect of treatment in patients with stroke using rotational thromboelastometryStanford et al., 2015
View PDF- Document ID
- 15292594297052570117
- Author
- Stanford S
- Sabra A
- Lawrence M
- Morris R
- Storton S
- Wani M
- Hawkins K
- Williams P
- Potter J
- Evans P
- Publication year
- Publication venue
- Journal of Stroke and Cerebrovascular Diseases
External Links
Snippet
Background Stroke is the second largest cause of death worldwide. Abnormalities in hemostasis play an important role in the pathophysiology of ischemic stroke (IS). These hemostatic defects can be detected using rotational thromboelastometry (ROTEM) as a …
- 210000004369 Blood 0 title abstract description 19
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/80—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood groups or blood types or red blood cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
- G01N2800/226—Thrombotic disorders, i.e. thrombo-embolism irrespective of location/organ involved, e.g. renal vein thrombosis, venous thrombosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/914—Hydrolases (3)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/487—Physical analysis of biological material of liquid biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
- G01N2800/324—Coronary artery diseases, e.g. angina pectoris, myocardial infarction
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment; Prognosis
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Rugeri et al. | Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography | |
Görlinger et al. | Fast interpretation of thromboelastometry in non-cardiac surgery: reliability in patients with hypo-, normo-, and hypercoagulability | |
Ives et al. | Hyperfibrinolysis elicited via thromboelastography predicts mortality in trauma | |
Wiinberg et al. | Thromboelastographic evaluation of hemostatic function in dogs with disseminated intravascular coagulation | |
Kornblith et al. | Obesity and clotting: body mass index independently contributes to hypercoagulability after injury | |
Kamal et al. | How to interpret and pursue an abnormal prothrombin time, activated partial thromboplastin time, and bleeding time in adults | |
Scarpelini et al. | Normal range values for thromboelastography in healthy adult volunteers | |
Vogel et al. | Admission rapid thrombelastography delivers real-time “actionable” data in pediatric trauma | |
Gorog et al. | Platelet function tests in clinical cardiology: unfulfilled expectations | |
Matsumoto et al. | Relationship between plasma D-dimer level and cerebral infarction volume in patients with nonvalvular atrial fibrillation | |
La Mura et al. | Resistance to thrombomodulin is associated with de novo portal vein thrombosis and low survival in patients with cirrhosis | |
Meyer et al. | Fibrinogen in trauma, an evaluation of thrombelastography and rotational thromboelastometry fibrinogen assays | |
Martinez et al. | Enhanced lysis and accelerated establishment of viscoelastic properties of fibrin clots are associated with pulmonary embolism | |
Scarlatescu et al. | The current status of viscoelastic testing in septic coagulopathy | |
Marti-Fabregas et al. | Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA | |
Allison et al. | Hematological issues in liver disease | |
Vedovati et al. | Global thromboelastometry in patients receiving direct oral anticoagulants: the RO-DOA study | |
Motta et al. | Reference intervals of citrated-native whole blood thromboelastography in premature neonates | |
Waha et al. | Effects of exercise and nutrition on the coagulation system during bedrest immobilization | |
Stanford et al. | Prospective evaluation of blood coagulability and effect of treatment in patients with stroke using rotational thromboelastometry | |
Lauridsen et al. | Coagulation profile after spontaneous intracerebral hemorrhage: a cohort study | |
Israels | Diagnostic evaluation of platelet function disorders in neonates and children: an update | |
Kang et al. | Association between thrombogenicity indices and coronary microvascular dysfunction in patients with acute myocardial infarction | |
Premkumar et al. | Principles, interpretation, and evidence-based role of viscoelastic point-of-care coagulation assays in cirrhosis and liver failure | |
Valke et al. | Fibrinolytic assays in bleeding of unknown cause: Improvement in diagnostic yield |